Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - metformini hydrochloridum, dapagliflozinum - compresse rivestite con film - metformini hydrochloridum 1000 mg, dapagliflozinum 10 mg ut dapagliflozinum propandiolum monohydricum, carmellosum natricum corresp. natrium 4.75 mg, hypromellosum, silica colloidalis hydrica, magnesii stearas, cellulosum microcristallinum, lactosum 48.00 mg, crospovidonum, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - dapagliflozinum, saxagliptinum - compresse rivestite con film - dapagliflozinum 10 mg ut dapagliflozinum propandiolum monohydricum, saxagliptinum 5 mg ut saxagliptini hydrochloridum, cellulosum microcristallinum, lactosum 40 mg, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidum hydrochloridum, natrii hydroxidum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: e 132, lacca, pro compresso obducto corresp. natrium max. 0.91 mg. - antidiabetico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - ertugliflozinum - compresse rivestite con film - ertugliflozinum 5 mg ertugliflozini l-pidolas, excipiens pro compresso haze. - il diabete mellito di tipo 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - ertugliflozinum, sitagliptinum - compresse rivestite con film - ertugliflozinum 5 mg ertugliflozini l-pidolas, sitagliptinum 100 mg a sitagliptini phosphas monohydricus, excipiens pro compresso haze. - il diabete mellito di tipo 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - ertugliflozinum, metformini hydrochloridum - compresse rivestite con film - ertugliflozinum 2.5 mg a ertugliflozini l-pidolas, metformini hydrochloridum 1000 mg, excipiens pro compresso haze. - il diabete mellito di tipo 2 - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

bayer ag - vericiguat - insufficienza cardiaca - terapia cardiaca - treatment of symptomatic chronic heart failure.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - vericiguatum - compresse rivestite con film - filmtablette: vericiguatum 2.50 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 61.20 mg, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, talcum, e 171, pro compresso obducto corresp. natrium 0.80 mg. - herzinsuffizienz - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - vericiguatum - compresse rivestite con film - filmtablette: vericiguatum 5.00 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 58.52 mg, magnesii stearas, natrii laurilsulfas, Überzug: e 172 (rubrum), hypromellosum, talcum, e 171, pro compresso obducto corresp. natrium 0.81 mg. - herzinsuffizienz - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - vericiguatum - compresse rivestite con film - filmtablette: vericiguatum 10.00 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, lactosum monohydricum 117.00 mg, magnesii stearas, natrii laurilsulfas, Überzug: e 172 (flavum), hypromellosum, talcum, e 171, pro compresso obducto corresp. natrium 1.65 mg. - herzinsuffizienz - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - farmaci usati nel diabete - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.